Company profile: CalciMedica
1.1 - Company Overview
Company description
- Provider of CRAC channel inhibitor therapies for acute and chronic inflammatory diseases, including Auxora, an IV CRAC inhibitor in development for acute pancreatitis, asparaginase-induced pancreatic toxicity, acute kidney injury, and ARDS, and oral CRAC inhibitors for conditions such as chronic pancreatitis and rheumatoid arthritis. Conducts clinical trials including CARPO, CRSPA, KOURAGE, and CARDEA.
Products and services
- Auxora: Intravenous-formulated CRAC channel inhibitor being developed to address acute pancreatitis, asparaginase-induced pancreatic toxicity, acute kidney injury, and acute respiratory distress syndrome
- CARPO Phase 2b Clinical Trial: Phase 2b clinical study evaluating Auxora in patients with acute pancreatitis accompanied by systemic inflammatory response syndrome (SIRS)
- CRAC Channel Inhibitors (Oral): Oral-formulated CRAC channel inhibitors under development for chronic inflammatory diseases such as chronic pancreatitis and rheumatoid arthritis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CalciMedica
iBio
HQ: United States
Website
- Description: Provider of AI-driven drug discovery and antibody therapeutic development solutions, including a discovery platform to validate difficult targets and develop antibody therapeutics; patented Epitope Engineering Engine; fully human antibody library; StableHu Antibody Optimizer; EngageTx CD3 T-cell engager panel; and a pipeline of immuno-oncology and other therapeutic candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iBio company profile →
Exagen
HQ: United States
Website
- Description: Provider of diagnostic and monitoring tests for autoimmune rheumatic diseases, including AVISE CTD and AVISE Lupus for SLE diagnosis using CB-CAPs, AVISE SLE Monitor for disease activity, AVISE SLE Prognostic for risk of thrombosis, cardiovascular events, lupus nephritis and neuropsychiatric lupus, AVISE APS for antiphospholipid syndrome and thrombosis risk, and AVISE MTX to assess methotrexate exposure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exagen company profile →
Cellenkos
HQ: United States
Website
- Description: Provider of clinical-stage allogeneic cord blood regulatory T cell therapeutics for autoimmune and inflammatory disorders, enabled by the proprietary CRANE platform for cell enrichment and differentiation and in-house cGMP manufacturing. Pipeline includes CK0801 for bone marrow failure syndromes, CK0802 for COVID-19 ARDS, and CK0804 for myelofibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellenkos company profile →
AB2 Bio
HQ: Switzerland
Website
- Description: Provider of drug discovery and development of best-in-class therapies for inflammatory diseases, including Tadekinig alfa, a recombinant IL-18 binding protein restoring the IL-18/IL-18BP balance; a proprietary assay to detect and measure free IL-18; and clinical programs in primary HLH (Phase III), secondary HLH/MAS, and adult-onset Still's disease (Phase II).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AB2 Bio company profile →
Hansa Biopharma
HQ: Sweden
Website
- Description: Provider of immunomodulatory treatments for rare immunological diseases, including Imlifidase, a first-generation IgG-cleaving enzyme for rapid inactivation of IgG antibodies via single intravenous treatment. Offers a proprietary enzyme technology platform targeting pathogenic antibodies across transplantation, autoimmunity, gene therapy and oncology, supported by strategic partnerships and sustainability initiatives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hansa Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CalciMedica
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CalciMedica
2.2 - Growth funds investing in similar companies to CalciMedica
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CalciMedica
4.2 - Public trading comparable groups for CalciMedica
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →